147 related articles for article (PubMed ID: 29274027)
21. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
22. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis.
Shaikh AY; Suryadevara S; Tripathi A; Ahmed M; Kane JL; Escobar J; Cerny J; Nath R; McManus DD; Shih J; McGuiness ME; Tighe DA; Meyer TE; Ramanathan M; Aurigemma GP
Echocardiography; 2016 Aug; 33(8):1166-77. PubMed ID: 27109429
[TBL] [Abstract][Full Text] [Related]
24. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy.
Lunning MA; Kutty S; Rome ET; Li L; Padiyath A; Loberiza F; Bociek RG; Bierman PJ; Vose JM; Armitage JO; Porter TR
Am J Clin Oncol; 2015 Aug; 38(4):377-81. PubMed ID: 24192805
[TBL] [Abstract][Full Text] [Related]
25. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling.
Mizia-Stec K; Gościńska A; Mizia M; Haberka M; Chmiel A; Poborski W; Gąsior Z
Kardiol Pol; 2013; 71(7):681-90. PubMed ID: 23907900
[TBL] [Abstract][Full Text] [Related]
26. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
27. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Kuittinen T; Husso-Saastamoinen M; Sipola P; Vuolteenaho O; Ala-Kopsala M; Nousiainen T; Jantunen E; Hartikainen J
Bone Marrow Transplant; 2005 Dec; 36(12):1077-82. PubMed ID: 16247436
[TBL] [Abstract][Full Text] [Related]
28. The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography.
Song F; Kang Y; Zhang C; Xu Y; Shi J; Guo Y; Zhang Q; Shu X; Cheng L
Cardiol J; 2017; 24(5):484-494. PubMed ID: 28353310
[TBL] [Abstract][Full Text] [Related]
29. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
30. A Novel Predictor of Chemotherapeutic Cardiotoxicity in Patients with Non-Hodgkin Lymphoma.
Gurdogan M; Ozkan U
Oncol Res Treat; 2019; 42(7-8):375-381. PubMed ID: 31132772
[TBL] [Abstract][Full Text] [Related]
31. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Vuolteenaho O; Ala-Kopsala M; Nousiainen T; Hartikainen J
Eur J Haematol; 2006 Aug; 77(2):120-7. PubMed ID: 16856907
[TBL] [Abstract][Full Text] [Related]
32. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
33. Potential usefulness of diastolic parameters measured by strain imaging echocardiography in the early prediction of chemotherapy-induced cardiotoxicity.
Hernandez-Suarez DF; López-Candales A
Med Hypotheses; 2017 Apr; 101():30-32. PubMed ID: 28351486
[TBL] [Abstract][Full Text] [Related]
34. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
35. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
[TBL] [Abstract][Full Text] [Related]
36. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
[TBL] [Abstract][Full Text] [Related]
37. [NT-proBNP and echocardiography for long-term left ventricular function assessment after acute myocardial infarction treated with primary angioplasty].
Swiatkiewicz I; Grubecki A; Koziński M; Fabiszak T; Białoszyński T; Sukiennik A; Kubica J
Pol Merkur Lekarski; 2006 Mar; 20(117):289-92. PubMed ID: 16780257
[TBL] [Abstract][Full Text] [Related]
38. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
Elbl L; Vasova I; Tomaskova I; Jedlicka F; Navratil M; Pospisil Z; Vorlicek J
Neoplasma; 2006; 53(2):174-81. PubMed ID: 16575475
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.
Di Lisi D; Leggio G; Vitale G; Arrotti S; Iacona R; Inciardi RM; Nobile D; Bonura F; Novo G; Russo A; Novo S
J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):270-5. PubMed ID: 25501904
[TBL] [Abstract][Full Text] [Related]
40. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
